117 related articles for article (PubMed ID: 12425485)
1. Total serum bile acids in renal transplanted patients receiving cyclosporine A.
Tripodi V; Nuñez M; Carducci C; Mamianetti A; Agost Carreño C
Clin Nephrol; 2002 Nov; 58(5):350-5. PubMed ID: 12425485
[TBL] [Abstract][Full Text] [Related]
2. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients.
Paydaş S; Balal M; Sertdemir Y; Seyrek N; Karayaylali I
Ren Fail; 2005; 27(4):409-13. PubMed ID: 16060128
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure.
Sugioka N; Fujimoto K; Tanaka Y; Fukushima K; Ito Y; Kokuhu T; Okamoto M; Yoshimura N; Takada K
Drug Metab Lett; 2009 Aug; 3(3):152-61. PubMed ID: 19702545
[TBL] [Abstract][Full Text] [Related]
4. Acute effect of CyA A (Neoral) on large artery hemodynamics in renal transplant patients.
Covic A; Mardare N; Gusbeth-Tatomir P; Buhaescu I; Goldsmith DJ
Kidney Int; 2005 Feb; 67(2):732-7. PubMed ID: 15673323
[TBL] [Abstract][Full Text] [Related]
5. The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts.
Khajehdehi P; Yip D; Bastani B
Clin Transplant; 1999 Apr; 13(2):176-80. PubMed ID: 10202614
[TBL] [Abstract][Full Text] [Related]
6. Effect of active infection on cytochrome P450-mediated metabolism of cyclosporine in renal transplant patients.
Hegazy SK; Adam AG; Hamdy NA; Khalafallah NM
Transpl Infect Dis; 2015 Jun; 17(3):350-60. PubMed ID: 25702620
[TBL] [Abstract][Full Text] [Related]
7. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
Sugioka N; Kokuhu T; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and 'monocyte reprogramming' after kidney transplant: a longitudinal study.
de Cal M; Silva S; Cruz D; Basso F; Corradi V; Lentini P; Nalesso F; Dissegna D; Goepel V; Chiaramonte S; Ronco C
Blood Purif; 2008; 26(1):105-10. PubMed ID: 18182807
[TBL] [Abstract][Full Text] [Related]
9. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function.
Perrea DN; Moulakakis KG; Poulakou MV; Vlachos IS; Papachristodoulou A; Kostakis AI
Int Urol Nephrol; 2006; 38(2):343-8. PubMed ID: 16868708
[TBL] [Abstract][Full Text] [Related]
10. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Lam H; Jeffery J; Sitar DS; Aoki FY
Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome.
Griveas I; Visvardis G; Papadopoulou D; Nakopolou L; Karanikas E; Gogos K; Stavianoudakis G
Artif Organs; 2010 Mar; 34(3):234-7. PubMed ID: 20447050
[TBL] [Abstract][Full Text] [Related]
12. Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients.
Assan R; Blanchet F; Feutren G; Timsit J; Larger E; Boitard C; Amiel C; Bach JF
Diabetes Metab Res Rev; 2002; 18(6):464-72. PubMed ID: 12469360
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A and purinergic receptors in rat kidney.
Halimi G; Sampol J; Clot-Faybesse O; Mercier L; Devaux C; Berland Y; Dussol B; Rochat H; Guieu R
Life Sci; 1999; 65(26):2801-13. PubMed ID: 10622269
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
Zawiasa A; Nowicki M
Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
[TBL] [Abstract][Full Text] [Related]
15. Correlations between cyclosporine concentrations at 2 hours post-dose and trough levels with functional outcomes in de novo lung transplant recipients.
Maziers N; Bulpa P; Jamart J; Delaunois L; Eucher P; Evrard P
Transplant Proc; 2012 Nov; 44(9):2880-4. PubMed ID: 23146546
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and incidence for lipid abnormalities in kidney transplant patients.
Ichimaru N; Yamanaka K; Kato T; Kakuta Y; Abe T; Imamura R; Nonomura N; Kaimori JY; Takahara S
Transplant Proc; 2015 Apr; 47(3):672-4. PubMed ID: 25891708
[TBL] [Abstract][Full Text] [Related]
17. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine trough levels in renal graft recipients.
Jauhari H; Wadhawan S; Yashpal ; Kumar A
J Indian Med Assoc; 1999 Nov; 97(11):476-7. PubMed ID: 10638120
[TBL] [Abstract][Full Text] [Related]
19. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center.
Tinawi M; Miller L; Bastani B
Clin Transplant; 1997 Feb; 11(1):1-8. PubMed ID: 9067686
[TBL] [Abstract][Full Text] [Related]
20. Ionised and total serum magnesium in renal transplant patients.
Mazzaferro S; Barberi S; Scarda A; Pasquali M; Rubino F; D'Erasmo E
J Nephrol; 2002; 15(3):275-80. PubMed ID: 12113599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
